In the company's second-quarter results call, Lilly's chief scientific officer Daniel Skovronsky revealed that orally active anti-tau drug LY3372689 – an O-GlcNAcase (OGA) inhibitor – failed a ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

Balancing Security and Citizen Experience in Public Sector Digital Services Two competing priorities are at play in the public sector —providing a modern, user-friendly digital experience to the ...